ECONOMICAL ASPECTS OF PHARMACOVIGILANCE IN THE PHARMACEUTICAL-INDUSTRY

The economical aspects of pharmacovigilance in the pharmaceutical indu stry can be assessed by two ways. First the balance between cost of av oiding adverse drug reactions (ADR) and cost of ADR should be evaluate d during the development. The company will have to take into account b oth efficacy and safety of its compound. However if it increases the c osts of avoiding ADR it will reduce the costs of avoiding ADR occuring after commercialisation. On the other hand the cost of side effects o f a marketed compound can also be appreciated. This assessment will al ways have to be comparative with an other drug and to take into accoun t the benefit of both drugs, if their efficacy is not deemed identical .